Sitagliptin Improves Glycemic Profile In Type 2 Diabetes Mild Renal Impairment | Latest News RSS feed

Sitagliptin Improves Glycemic Profile In Type 2 Diabetes Mild Renal Impairment - Latest News


Sitagliptin improves glycemic profile in type 2 diabetes, mild renal impairment

Adults with type 2 diabetes, mild renal insufficiency and an elevated HbA1c assigned the DPP-IV inhibitor sitagliptin experienced greater improvements in glycemic profile vs. similar patients assigned ... read more

Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA ® (sitagliptin)

“These studies further support the clinical profile of JANUVIA ... Safety and Efficacy of Sitagliptin Compared with Dapagliflozin in Subjects with Type 2 Diabetes, Mild Renal Impairment and Inadequate ... read more

Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes

Sitagliptin monotherapy improved indices of glycemic control compared to placebo and was generally well-tolerated in patients with type 2 diabetes. The glycemic response ... Based on this favorable ... read more

Looking for another news?


BYDUREON(TM) Safety and Tolerability Pooled Summary Data Presented at ADA 2010

Hypoglycemic events were lower with BYDUREON, and composite exposure-adjusted incidence rates were similar for BYDUREON versus pooled comparators for pancreatitis, gall-bladder AEs, renal impairment . ... read more


Differential pharmacology and clinical utility of empagliflozin in type 2 diabetes

Empagliflozin treatment demonstrates consistent reductions in hemoglobin A1c, fasting plasma glucose, body weight, and blood pressure in individuals with type 2 diabetes. Improvements in glycemic ... ... read more

PRESS RELEASE: Merck's Januvia Wins New Uses but Risks Outlined

JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes ... is needed for patients with mild to moderate hepatic insufficiency or ... read more

Five new studies at major medical meeting further demonstrate clinical experience for JANUVIA™ (sitagliptin)

JANUVIA is indicated, as an adjunct to diet and exercise, to improve glycemic control in adult patients with type 2 diabetes. JANUVIA should not ... history of a serious hypersensitivity reaction to ... read more

Efficacy And Safety Of Sodium Glucose Co-Transport-2 (Sglt-2) Inhibitors In Type 2 Diabetes: A Metanalysis Of Randomised Clinical Trials.

Sodium glucose co-transport-2 (SGLT-2) inhibitors ... inhibitors in the kidney, there is a concern that they may induce renal impairment. ... Sodium-glucose cotransporter 2 inhibitors and risk of ... read more

Elcelyx 'Guts' Conventional Thinking on Metformin

The company plans to initiate a pharmacokinetic study this summer in Type II diabetes patients with mild, moderate and severe renal impairment ... 2 inhibitor, provided greater improvements in blood ... read more

Pfizer 2017: Beyond The Blockbusters

Executives say business in 2016 was further strengthened with the addition of new products, including Eucrisa for mild to moderate ... oral SGLT-2 inhibitor in development to help improve glycemic ... read more

Merck Presents New Data from the Comparative Trials with Sitagliptin (CompoSIT) Clinical Trial Program with JANUVIA® (sitagliptin)

“These studies further support the clinical profile of JANUVIA ... Safety and Efficacy of Sitagliptin Compared with Dapagliflozin in Subjects with Type 2 Diabetes, Mild Renal Impairment and Inadequate ... read more



FeedsRSS Created by. Full RSS Feed | Privacy Policy | Contact Us